Response to: 'Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'' by Jeny et al

Ann Rheum Dis. 2022 Dec;81(12):e242. doi: 10.1136/annrheumdis-2020-218983. Epub 2020 Oct 1.

Authors

Andrea Hermina Györfi¹, Georg Schett¹, Jörg H W Distler²

Affiliations

¹ Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
² Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany joerg.distler@uk-erlangen.de.

PMID: 33004332
DOI: 10.1136/annrheumdis-2020-218983

No abstract available

Keywords: biological therapy; glucocorticoids; sarcoidosis.

Publication types

Comment

MeSH terms

COVID-19*
Glucocorticoids / therapeutic use
Humans
Recurrence
Sarcoidosis* / complications
Sarcoidosis* / drug therapy

Substances

Glucocorticoids